The Special Testing and Research Laboratory’s Emerging Trends Program compiled the data for this report through a query of archived seizure and analysis information from drug evidence analyzed by the Drug Enforcement Administration’s laboratory system. This data is representative of drug evidence seized and analyzed in the date ranges annotated. This is not a comprehensive list of all new psychoactive substances and is not representative of all evidence analyzed by DEA. This data is an annual snapshot of the new psychoactive substance market in the United States.

**SYNTHETIC CANNABINOID IDENTIFICATIONS**

**THERE WERE 134 SYNTHETIC CANNABINOID IDENTIFICATIONS IN CY2020. THIS REPRESENTS AN APPROXIMATELY 23% DECREASE FROM CY2019. 5F-MDMB-PICA AND MDMB-4EN-PINACA WERE THE MOST COMMONLY REPORTED SYNTHETIC CANNABINOIDS ACCOUNTING FOR APPROXIMATELY 66% OF THE IDENTIFICATIONS.**

<table>
<thead>
<tr>
<th>Substance</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>5F-UR-144</td>
<td>1</td>
</tr>
<tr>
<td>4-CN-CUMYL-BUTINACA</td>
<td>2</td>
</tr>
<tr>
<td>FUB-AMB</td>
<td>3</td>
</tr>
<tr>
<td>ADB-FUBINACA</td>
<td>3</td>
</tr>
<tr>
<td>5F-MDMB-PINACA</td>
<td>4</td>
</tr>
<tr>
<td>FUB-144</td>
<td>5</td>
</tr>
<tr>
<td>4F-MDMB-BUTICA</td>
<td>5</td>
</tr>
<tr>
<td>4F-MDMB-BUTINACA</td>
<td>21</td>
</tr>
<tr>
<td>*MDMB-4en-PINACA</td>
<td>42</td>
</tr>
<tr>
<td>5F-MDMB-PICA</td>
<td>47</td>
</tr>
</tbody>
</table>

* Indicates that the substance was reported for the first time this reporting period.

**CATHINONES**

**THERE WERE 200 CATHINONE IDENTIFICATIONS THIS REPORTING PERIOD. THIS REPRESENTS AN APPROXIMATELY 9% INCREASE FROM CY2019. EUTYLONE WAS THE MOST REPORTED CATHINONE, ACCOUNTING FOR APPROXIMATELY 77% OF THE IDENTIFICATIONS.**

<table>
<thead>
<tr>
<th>Substance</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-Chloropentedrone</td>
<td>1</td>
</tr>
<tr>
<td>4-CEC</td>
<td>1</td>
</tr>
<tr>
<td>N-Ethylpentylone</td>
<td>3</td>
</tr>
<tr>
<td>N-Ethylheptedrone</td>
<td>3</td>
</tr>
<tr>
<td>N-Ethylhexedrone</td>
<td>4</td>
</tr>
<tr>
<td>Ethylone</td>
<td>4</td>
</tr>
<tr>
<td>*3-MMC</td>
<td>4</td>
</tr>
<tr>
<td>CEC = Chloroethcathinone</td>
<td>4</td>
</tr>
<tr>
<td>MMC = Methylmethcathinone</td>
<td>4</td>
</tr>
<tr>
<td>MDPT = Methylenedioxy-N-tetrahydro-2,3-benzylicathinone</td>
<td>5</td>
</tr>
<tr>
<td>N-Butylpentylone</td>
<td>5</td>
</tr>
<tr>
<td>4CI-N,N-Dimethylcathinone</td>
<td>5</td>
</tr>
<tr>
<td>BMDP = Methylenedioxy-N-benzycathinone</td>
<td>5</td>
</tr>
<tr>
<td><strong>Eutylone</strong></td>
<td>154</td>
</tr>
</tbody>
</table>

* Indicates that the substance was reported for the first time this reporting period.

An identification is made when authenticated reference material is available for comparison. When reference material is not available, the drug evidence is identified as “substance unconfirmed” or “inconclusive.” A single unit of drug evidence may have multiple sub-units. For the purposes of this document, each unit of drug evidence counts as one identification regardless of the number of sub-units. Some seized drug evidence contains more than one active ingredient; therefore, more than one identification can be made for a single unit.

The term new psychoactive substance (NPS) describes a recently emerged drug that may pose a public health threat. This includes synthetic cannabinoids, substituted cathinones, phenethylamines, opioids, tryptamines, benzodiazepines, and a variety of other chemical classes. Due to the increase in seizures over the last several years, fentanyl is also included in this report.
OPIOIDS/ANALGESICS

THERE WERE 4862 IDENTIFICATIONS OF FENTANYL, FENTANYL-RELATED COMPOUNDS AND OTHER NEW SYNTHETIC OPIOIDS. THIS ACCOUNTS FOR AN APPROXIMATELY 10% DECREASE IN IDENTIFICATIONS FROM 2019. FENTANYL ACCOUNTED FOR APPROXIMATELY 89% OF THE IDENTIFICATIONS. THE NEXT MOST PROMINENT SUBSTANCE, 4-ANPP, ACCOUNTED FOR APPROXIMATELY 5% OF THE IDENTIFICATIONS. OF THE 4323 FENTANYL IDENTIFICATIONS, FENTANYL WAS FOUND AS THE ONLY CONTROLLED SUBSTANCE IN APPROXIMATELY 53% OF THE IDENTIFICATIONS AND WAS FOUND WITH HEROIN IN APPROXIMATELY 31% OF THE IDENTIFICATIONS.

* β'-Phenyl Fentanyl
  U-47700
* Norfentanyl
  N-Methyl Norfentanyl
  N-Benzyl-p-fluoro Norfentanyl
Despropionyl p-Fluorofentanyl
4'-Methyl Acetyl Fentanyl
3-Methylfentanyl
2-Thiouranyl Fentanyl
2-Furanyl Fentanyl
* Borphine
* p-Fluorofentanyl
NPP
Methoxyacetyl fentanyl
2-Furanylbenzyl Fentanyl
* Isotonitazene
* Furanyl UF-17
4-FIBF
Butyryl Fentanyl
Valeryl Fentanyl
Carfentanil
Acetyl fentanyl
4-ANPP
Fentanyl

HALLUCINOGENS


OTHER

The “other” category includes substances that could not be confirmed, psychoactive plants, PCP related substances, benzofurans, hallucinogens, tryptamines, and amphetamines.

THERE WERE 42 INSTANCES OF INCONCLUSIVE REPORTS DURING THIS REPORTING PERIOD. ADDITIONALLY, THERE WERE 5 IDENTIFICATIONS EACH OF 2F-DESLOROKETAMINE, 2-METHOXYMETHAMPHETAMINE AND MITRAGYNINE. 2-OXO-PCE WAS IDENTIFIED 3 TIMES. DESLOROKETAMINE AND N-(1,4-DIMETHYL PENTYL)-3,4-DIMETHYLMETHAMPHETAMINE WERE IDENTIFIED 2 TIMES EACH. ADDITIONALLY, TFMP AND A SUBSTANCE REPORTED AS “UNKNOWN” WERE REPORTED 1 TIME EACH. N-(1,4-DIMETHYL PENTYL)-3,4-DMA, DIMETHAZINE AND METHYL STENBOLONE WERE REPORTED FOR THE FIRST TIME IN CY2020.

Tryptamines

- 5-MeO-DMT
- 4-AcO-DMT
- 5-MeO-DBT

Steroids

- * Methylstenbolone
- * Dimethazine
- Dehydrochloromethyl testosterone

BENZODIAZEPINES

THERE WERE 295 IDENTIFICATIONS OF DESIGNER BENZODIAZEPINES DURING THIS REPORTING PERIOD. THIS REPRESENTS AN APPROXIMATELY 157% INCREASE FROM CY2019. FLUALPRAZOLAM AND ETIZOLAM WERE THE MOST REPORTED DESIGNER BENZODIAZEPINES ACCOUNTING FOR APPROXIMATELY 81% OF THE IDENTIFICATIONS.

- Desalkyl flurazepam
- Deschloroetizolam
- Adinazolam
- Flubromazolam
- Clonazolam
- Etizolam
- Fkualprazolam

* Indicates that the substance was reported for the first time this reporting period

Questions about this data are welcome and may be directed to the DEA Emerging Trends Program at 703-668-3300 or DEA.Emerging.Trends@usdoj.gov.
NPS IDENTIFICATIONS OF SELECT SUBSTANCES
CY2016 TO CY2020

This data is representative of drug evidence seized and analyzed 01/01/2016 to 12/31/2020. The number of identifications for each substance may change as exhibits are analyzed from the laboratory system backlog.

Prominent Opioids

Prominent Cathinones

Prominent Benzodiazepines

Unconfirmed Substances/Inconclusive Reports